Mobile Sensor Technologies to Assess General Symptomology of People With Cancer
Background: Many digital devices, such as smartphones and activity monitors, have sensors to collect and track health data. Researchers believe these devices may be able to transform the quality of clinical research and healthcare. They believe they may be able to help assess the symptoms, response to therapy, and quality of life of people with cancer. Objective: To collect data from people with cancer using an Apple iPhone alone or together with an Apple Watch in order to assess their symptoms and activity levels. Eligibility: People ages 18 years and over who have cancer and receiving treatment for their cancer in another NIH protocol Design: Participants will be screened with their medical records. Participants will have a baseline visit. They will have visits every 2 4 weeks based on the treatment protocol in which they are co-enrolled. Then they will have a follow-up visit 4 months after the baseline visit. Visits include: Medical history Physical exam Karnofsky Performance Scale/Eastern Cooperative Oncology Group performance status to see how their disease affects daily activities The study team will use an iPhone to collect data. This includes a 6-minute walk test and tests of hearing, reaction time, and cognitive status. Questionnaires If participants have an iPhone, an Apple Watch will be provided to them after training at the baseline visit. Continuous measurement of their activity will be recorded by the watch between 2 visits. They will wear the watch while they are on study. They will wear the watch while it is not being charged. They should charge the watch at night time. They will have the watch for 4 months.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 6, 2026 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- National Cancer Institute (NCI)
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Signed written informed consent.
- Male or female subjects aged greater than or equal to 18 years.
- A cancer diagnosis.
- Participant should be under active treatment for cancer on a protocol at NIH.
- Active central nervous system (CNS) metastases.
- Known current alcohol or drug abuse.
- Current marijuana use, including for medicinal purposes.
- Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- Color blindness to any of the following colors: green, yellow, and/or red.
- Legal incapacity or limited legal capacity.
- Cancer survivors who are not actively receiving treatment.
- Non-English speaking subjects.
- Resting heart rate at screening, higher than 120 beats per minute.
- Systolic blood pressure at screening, higher than 180 mmHg.
- Diastolic blood pressure at screening, higher than 100 mmHg.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- National Institutes of Health Clinical CenterBethesda, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 6, 2026. Always confirm current availability with the study team.